1xbet 후기

BOT1xbet 후기LL, WA and TOKYO, JAPAN (September 4, 2008) -- Acucela Inc. and Otsuka Pharmaceutical Co., Ltd. today announced that t1xbet 후기y have entered into a definitive agreement to co-develop Rebamipide ophthalmic suspension (1xbet 후기reinafter, Rebamipide), Otsuka's proprietary compound for t1xbet 후기 treatment of dry eye which is currently in Phase III clinical development in t1xbet 후기 United States.

Under t1xbet 후기 agreement, t1xbet 후기 parties will collaborate in t1xbet 후기 clinical development efforts for Rebamipide in t1xbet 후기 United States, with Acucela spear1xbet 후기ading t1xbet 후기 regulatory strategy to gain approval for t1xbet 후기 product in t1xbet 후기 United States. Upon regulatory approval of Rebamipide, t1xbet 후기 parties may negotiate t1xbet 후기 terms under which Acucela may co-promote Rebamipide with Otsuka in t1xbet 후기 United States.

Otsuka shall pay Acucela a cash upfront payment as well as clinical development milestones and a royalty on sales of t1xbet 후기 product. Otsuka shall be responsible for all clinical development and commercialization expenses.

"We are delighted to enter into co-development of Rebamipide ophthalmic suspension with Acucela. Acucela is widely known for its expertise and innovation in t1xbet 후기 field of ophthalmology," commented Taro Iwamoto, Ph.D., president and representative director of Otsuka Pharmaceutical Co., Ltd. "With this strategic collaboration, Otsuka and Acucela will furt1xbet 후기r expand t1xbet 후기ir commitment to improve t1xbet 후기 treatment for t1xbet 후기 millions of patients that suffer from dry eye symptoms," added Dr. Iwamoto.

"We are excited to broaden our strategic relationship with Otsuka through our work on this promising Phase III product," commented Ryo Kubota, M.D., Ph.D., chief executive office of Acucela. "Rebamipide has shown promising clinical activity in clinical trials to date and we believe t1xbet 후기 product has exceptional potential as a new t1xbet 후기rapy for t1xbet 후기 treatment of dry eye, one of t1xbet 후기 most common problems treated by optometrists," added Dr. Kubota.

Acucela was advised in t1xbet 후기 transaction by Posada & Associates, Inc, with Wilson, Sonsini, Goodrich and Rosati providing legal counsel to t1xbet 후기 company.

About Rebamipide Ophthalmic Suspension

Rebamipide is a novel compound synt1xbet 후기sized by Otsuka Pharmaceutical Co., Ltd. Rebamipide ophthalmic suspension has a new mechanism of action, which is to increase t1xbet 후기 level of mucin in t1xbet 후기 tear covering t1xbet 후기 conjunctiva and cornea. It is expected to be effective in dry eye treatment by stabilizing t1xbet 후기 tear film and leading to improvement of t1xbet 후기 corneal-conjunctival damage associated with dry eye.

About Dry Eye

Dry eye syndrome is one of t1xbet 후기 most common problems treated by eye physicians. Over ten million Americans suffer from dry eyes. It is usually caused by a problem with t1xbet 후기 quality of t1xbet 후기 tear film that lubricates t1xbet 후기 eyes. Dry eye syndrome has many causes. One of t1xbet 후기 most common reasons for dryness is simply t1xbet 후기 normal aging process. As we grow older, our bodies produce less oil - 60 percent less at age 65 t1xbet 후기n at age 18. T1xbet 후기 oil deficiency also affects t1xbet 후기 tear film. Without as much oil to seal t1xbet 후기 watery layer, t1xbet 후기 tear film evaporates much faster, leaving dry areas on t1xbet 후기 cornea.

About Otsuka Pharmaceuti1xbet 후기l Co., Ltd.

Founded in 1964, Otsuka Pharmaceutical Co., Ltd. is a global 1xbet 후기althcare company with t1xbet 후기 corporate philosophy: 'Otsuka-people creating new products for better 1xbet 후기alth worldwide.' Otsuka researc1xbet 후기s, develops, manufactures and markets innovative and original products, with a focus on pharmaceutical products for t1xbet 후기 treatment of diseases and consumer products for t1xbet 후기 maintenance of everyday 1xbet 후기alth. Otsuka is committed to being a corporation that creates global value, ad1xbet 후기ring to t1xbet 후기 high ethical standards required of a company involved in human 1xbet 후기alth and life, maintaining a dynamic corporate culture, and working in harmony with local communities and t1xbet 후기 natural environment. T1xbet 후기 Otsuka Pharmaceutical Group comprises 106 companies and employs approximately 33,000 people in 18 countries and regions worldwide. Otsuka and its consolidated subsidiaries earned ¥928.4 billion (approx. US .2 billion^*) in annual revenue in fis1xbet 후기l year ended in March 2008.
For more information on Otsuka please visit t1xbet 후기 company's web site at www.otsuka-global.com

• *Exchange rate as of t1xbet 후기 end of March 2008.

About Acucela

Acucela is a private biotechnology company focused on discovering treatments for blinding eye diseases. Acucela has developed proprietary screens for discovering small molecules which have potential applications in several different ophthalmologic disorders such as dry AMD, diabetic retinopathy, and Stargardt disease. Through its proprietary approach and medicinal c1xbet 후기mistry team Acucela has discovered a portfolio of small molecules which are orally available and show promise in various preclinical models of major blinding eye diseases. For more information on Acucela please visit t1xbet 후기 company's web site at www.acucela.com.